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Abstract
Background: Individuals belonging to the same family share a number of genetic as well as
environmental circumstances that may condition a common SBP level. Among the genetic factors,
the angiotensin converting enzyme (ACE) gene I/D polymorphism appears as a possible candidate
as it might influence both SBP and the pharmacological effect of ACE inhibitors. We aimed to
combine genetic epidemiology with public health ideas concerning life-course and multilevel
epidemiology in order to understand the role of familial factors regarding individual SBP.
Methods: We applied multilevel regression analysis on 1926 individuals nested within 438 families
from South Sweden. Modelling familial SBP variance as a function of age and use of ACE inhibitors
we calculates a variance partition coefficient and the proportional change in familial SBP variance
attributable to differences in ACE gene I/D polymorphism
Results:  Our results suggest the existence of genetic or environmental circumstances that
produce a considerable familial clustering of SBP, especially among individuals using ACE-inhibitors.
However, ACE gene I/D polymorphism seems to play a minor role in this context. In addition,
familial factors – genetic, environmental or their interaction – shape SBP among non-users of ACE
inhibitors but their effect is expressed later in the life-course.
Conclusion: Strategies directed to prevent hypertension should be launched in younger rather
than in older ages and both prevention of hypertension and its treatment with ACE inhibitors
should be focused on families rather than on individuals.
Background
Individuals belonging to the same family share a number
of genetic as well as environmental factors like common
physical environment, socioeconomic position, dietary
habits, familial attitudes and health believes, etc. Such cir-
cumstances may condition a common level of systolic
blood pressure (SBP) that may express itself as a clustering
of SBP level within families.
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It is known that SBP is a central risk factor for cardiovas-
cular diseases [1]. SBP level increases with age and also is
conditioned by genetic factors [2]. Moreover, in presence
of established hypertension pharmacological treatment of
blood pressure is as well a strong determinant of SBP level
for obvious reasons.
One of the main mechanisms for blood pressure homeos-
tasis is the renin angiotensin aldosterone system (RAAS)
and a common effective group of antihypertensive drugs
are angiotensin converting enzyme (ACE) inhibitors. By
blocking the ACE these drugs reduce the levels of angi-
otensin II and thereby decrease vasoconstriction and renal
sodium reabsorption which, in turn, leads to lower blood
pressure [3]. Among the genetic factors behind a possible
familial clustering of SBP, the angiotensin converting
enzyme (ACE) gene I/D polymorphism appears as a pos-
sible candidate. ACE levels are highly inherited and show
a great interindividual variation [4]. It has been shown
that the ACE gene (chromosome 17q23) harbours an
insertion/deletion (I/D) polymorphism that accounts for
47% of the variance in plasma ACE concentration [5].
However, it is possible that the I/D polymorphism per se
may not be responsible for the ACE levels [6] but rather an
unknown nearby polymorphism that is in strong linkage
disequilibrium with the ACE gene I/D locus [7]. It is thus
plausible that the pharmacological effect of ACE inhibi-
tors drugs could be modified by familial factors, particu-
larly by familial differences in the prevalence of the ACE
gene I/D polymorphism. It has also been suggested that
ACE gene polymorphism may modulate the physiological
age related changes in blood pressure [8,9].
Therefore, we expected to find a familial clustering for
both ACE I/D polymorphism and for SBP level. If this
were true, it might also be possible that familial differ-
ences in ACE I/D polymorphism could explain some of
the familial differences in SBP and thus clustering of SBP.
This possible phenomenon might differ by age and use of
ACE inhibitors.
Considering all those factors (i.e. family environment,
blood pressure, individual age, pharmacological treat-
ment with ACE inhibitors and the ACE gene I/D polymor-
phism) simultaneously is a methodological challenge. In
the present study we aim to apply a methodological
approach based on multilevel regression analysis [10,11]
that may be useful in this context [12,13]. By doing so, we
aimed to combine genetic epidemiology with public
health ideas concerning life-course and multilevel epide-
miology in order to understand the role of familial factors
regarding individual SBP.
Methods
Participants
In this study we pooled three population based family
materials from South Sweden consisting of at least two
siblings and, when available, their relatives and spouses.
The information was collected during 1996–2000 in all
the three samples. Two of them (Malmö-B and Skara)
included siblings with established hypertension, whereas
one (Malmö A) included siblings with a positive family
history of established hypertension but presence of estab-
lished hypertension was not a necessary inclusion crite-
rion. In Malmö-A, probands were identified in the Malmö
Diet and Cancer [14] and Malmö Preventive Project [15]
databases. In Malmö B, probands were identified at five
different primary health care centres in southern Sweden.
In the Skara sample, probands and their families were
ascertained from patients diagnosed with hypertension
from two earlier population based surveys in Skara, one
investigation of patients with hypertension and diabetes
in primary health care [16], and one investigation of a
random sample of Skara population [17].
The local ethics committee at Gothenburg and Lund Uni-
versity approved the study protocols and all participants
gave their informed consent.
Assessment of blood pressure
All subjects were investigated in the morning after at least
10-hours fast. Blood pressure was measured in the right
brachial artery with subjects in the supine position after at
least 5–15 minutes rest by specially trained nurses using a
using Tricuff® sphygmomanometer for adjustment of cuff
size to arm circumference [18]. The systolic and diastolic
blood pressures were recorded to the nearest 2 mmHg and
the mean of three measurements was recorded. Estab-
lished hypertension was defined as having at least three
consecutive blood pressure recordings at different occa-
sions ≥ 160 mmHg systolic and/or ≥ 90 mmHg diastolic
or being on medication for treatment of blood pressure.
Genotyping
High molecular DNA was extracted from blood leucocytes
using standard techniques [19]. The ACE gene I/D poly-
morphism was genotyped according to the methods
described by Rigat et al [20] except that 1.5 mmol MgCl2
and 1% formamid were used in the PCR reaction. To
exclude mistyping of the heterozygotes as DD homozy-
gotes all the DD genotypes samples were confirmed with
an insertion specific PCR [21].
Use of medication
In order to assess current pharmacological treatment the
subjects were asked to bring receipts and pill boxes and
the information was asserted by a face to face interview
performed by specially trained nurses. ACE inhibitorsBMC Medical Genetics 2006, 7:14 http://www.biomedcentral.com/1471-2350/7/14
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were defined according the Anatomical Therapeutic
Chemical classification system code C09A [22].
Statistical analysis: multilevel regression analysis
Individual SBP was analyzed by multilevel linear regres-
sions models [10,23] with individuals at the first level and
families (i.e., pedigrees) at the second level. Multilevel
regression analysis is a very appropriate technique for per-
forming variance analysis in unbalanced clusters as fami-
lies [23].
We fitted three models. Model I did not include any
explanatory variables and only focused on decomposing
the total SBP variance (VTotal) in its individual (VI) and
familial (VF) components. In model II we included dummy
variables for the original study samples (Skara, Malmö-A
and B) individual age, and for use of ACE inhibitors. In
the last model III we included the ACE gene I/D polymor-
phism in addition to the variables already included in
model II. For the statistical analysis we constructed dummy
variables for the presence or absence of homozygosis II,
homozygosis DD, and heterozygosis ID, and used
homozygosis II as reference in the comparisons. In model
II and III we investigate family-individual interaction by
allowing the slope of the association between on the one
hand SBP and on the other age or ACE inhibitors to be
random at the family level. That is, we investigate whether
the family level modified those individual level associa-
tions.
We calculated the Variance Partition Coefficient (VPC).
The VPC is a measure of the extent to which members of
a family resemble each other more than they resemble
individuals from other families in relation to SBP level.
The VPC is the percentage of the total variance (VF + VI) in
SBP that is attributed to the family level (VF) and is, there-
fore, a measure of clustering. In the simplest form (model
i) the VPC corresponds to the intraclass correlation coeffi-
cient, being a measure of general clustering of individual
SBP in the families.
In models II and III, because of the existence of random
slopes at the familial level the variance of the slope of the
association between SBP and age as well as the variance of
the slope of the association between SBP and use of ACE
inhibitors are also a coefficient in a function that describes
how the between-families variation in SBP differs in indi-
viduals with different age and use of ACE inhibitors. This
variance function includes also the intercept variance and
the covariances. The output of this variance function was
obtained from the software used for the multilevel regres-
sion analysis. [11,24] By means of this variance function
we calculated the VPC as a function of age and use of ACE
inhibitors which provided information on the relevance
of familial factors for understanding SBP differences in
specific groups of individuals (i.e., defined by age and use
of ACE inhibitors). A large VPC would indicate that famil-
ial factors are important in order to understand individual
SBP differences. On the other hand, a VPC close to zero
would indicate that the families exert only a small influ-
ence on individual SBP variance.
Using the VF from the models before (Model II) and after
(Model III) adjustment for ACE I/D gene polymorphism
we calculated the absolute [VF before - VF after] and the rel-
ative [((VF before - VF after)/VF before) × 100] change in
variance.
The precision of the estimates was appraised by their SE.
Parameters were tested in an approximate manner using a
normal test (i.e., the ratio of an estimated variance to its
standard error) and Wald statistic with a chi-square distri-
bution [25], and calculated exact p-values. A p-value
greater than 0.05 was considered non-significant (NS).
In addition to familial clustering (i.e., VPC) of SBP we also
calculated the familial clustering of homozygosis II,
homozygosis DD, and heterozygosis ID, as well as the
familial clustering of ACE inhibitors use. Since these vari-
ables are binary we applied multilevel logistic regression
analysis [25] and calculated the VPC using the latent vari-
able threshold method recommended by Snijders [23].
The software MLwiN, Version 2 [24] was used to perform
the analyses. Regression parameters were estimated using
Markov Chain Monte Carlo (MCMC). We use the Devi-
ance Information Criterion (DIC) to compare the good-
ness of the fit of consecutive models. [24]
Results
The characteristics of the population are presented in
Table 1. Mean SBP was lowest in Malmö-A and highest in
Skara. The prevalence of the different forms of ACE gene
I/D polymorphism showed slight differences between the
three pooled datasets (p = 0.014), and the prevalence of
use of ACE inhibitors was highest in Skara and lowest in
Malmö-A. Table 2 shows the distribution of the families
according their size. The number of relatives varied but
most of the families had between two and five relatives.
Table 3 shows the results of the multilevel linear regres-
sion analysis. The regression coefficients in the fixed
effects section of the model II informs that for each year of
age SBP increases by 0.9 mmHg. Users of ACE inhibitors
have in average 4.5 mmHg higher SBP than non-users
(i.e., users of other antihypertensive medication or indi-
viduals without pharmacological treatment of hyperten-
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sion). Inclusion of the ACE gene I/D polymorphism in
model III did not affect the associations (regression coef-
ficients) estimated in model II. Compared with individu-
als homozygous for II, heterozygous ID and homozygous
DD individuals presented a lower SBP but this difference
was only significant for the ID group (p = 0.025).
Table 3 also presents the components of variance analysis
(i.e. random effects). Model I informed that individuals
from the same family shared a common level of SBP since
9% of the individual differences in SBP were actually at
the family level (VPC = 9%). Inclusion of random slopes
for age and use of ACE inhibitors in model II discovered a
considerably familial heterogeneity. Figure 1 shows the
familial differences in the slope of the association
between on the one hand age (A) and use of ACE inhibi-
tors (B) and on other hand SBP level. Simple visual obser-
vation suggests that familial differences in SBP increased
by age and were higher in users of ACE inhibitors.
Figure 2 illustrates that because of the existence of slope
variance the familial SBP variance (Figure 2A) and the
VPC (Figure 2B) became a function of age and use of ACE
inhibitors. In users of ACE inhibitors familial variance
and clustering of SBP are already evident in younger ages,
but in non-users of ACE inhibitors these parameters seem
increase with age. Inclusion of the ACE gene I/D polymor-
phism in model III (red colour) reduces slightly the famil-
ial clustering of SBP among users of ACE inhibitors but it
did not improve the statistical goodness of the fit (Table
3). The information presented in figure 2 is also numeri-
cally illustrated in table 4.
The results of the complementary logistic regression anal-
yses showed a strong familial genetic clustering for the dif-
ferent forms of the ACE gene I/D polymorphism, specially
for homozygous forms DD (VPC = 43%) and II (VPC =
37%) and in a lower degree for the heterozygous form ID
(VPC = 15%). Use if ACE inhibitors was also clustered
within families (VPC = 9%).
Discussion
The multilevel regression analysis allowed us to study the
distribution of blood pressure in families along individual
age and use of ACE inhibitors and simultaneously investi-
gate the role of ACE gene I/D polymorphism in this con-
text.
We observed that SBP level clustered within families to an
appreciable degree, and that this clustering increased con-
siderably with age in people that did not use ACE-inhibi-
tors. This fact suggests the existence of specific familial
Table 2: Family size in the study sample
Family size Number of individuals Number of families Percentage
2 120 60 13.7
3 321 107 24.4
4 512 128 29.2
5 260 52 11.9
6 192 32 7.3
7 133 19 4.3
8 112 14 3.2
9 108 12 2.7
10 60 6 1.4
≥11 108 8 1.8
Total 1926 438 100
Table 1: Characteristics of the 1926 individuals from 438 Swedish families with history of hypertension
Whole Sample Malmö Sample A Sample B Skara
Number of people 1926 581 1100 245
Number of families 438 145 223 70
Age (mean years) 54 51 54 60
M e n  ( % ) 4 74 94 74 1
Systolic blood pressure (mean mmHg) 139 131 142 146
Use of ACE-inhibitors (%) 10 8 11 13
ACE gene I/D polymorphism
II (%) 23 23 23 22
I D  ( % ) 4 85 24 74 8
D D  ( % ) 2 62 42 92 1
ACE = Angiotensin converting enzyme inhibitors. I = insertion, D = deletionBMC Medical Genetics 2006, 7:14 http://www.biomedcentral.com/1471-2350/7/14
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genetic or environmental factors influencing individual
SBP, and that the effect of these familial factors express
later in the life course. In fact, familial differences in SBP
were large in the elderly but very small in youth people.
It is possible that both familial genetic and environmental
circumstances (e.g., common physical environment, soci-
oeconomic position, dietary habits, familial attitudes and
health believes, etc) affecting SBP act only after latency
period. It is also probable that genetic susceptibility affects
SBP level only when the effects of familial environmental
factors become fully developed through the individual's
life course. As a hypothetical example, learned familial
behaviours may lead to obesity in adulthood, which in
turn increases the risk of hypertension later in life in peo-
ple with certain genetic predisposition. It is possible that
these kinds of mechanisms could explain our results.
However, the database used in this investigation was not
primarily design to answer those question and informa-
tion on socioeconomic and behavioural factors was not
available. Moreover our study was cross-sectional and we
cannot exclude – even if we dot believe it probable – the
existence of a cohort effect confounding the age related
familial differences in SBP.
In the present study we cannot differentiate between
genetic effects (apart from the minor effect of the ACE I/D
polymorphism) and effects of familial environment on
SBP. However, it is reasonable to believe that, to a large
extent, genetic and environmental factors determining
SBP interact with each other throughout life. Thus, genetic
susceptibility to high SBP is likely to be modified by
reducing environmental risk factor load. Therefore, our
results suggest that acting on familial environmental fac-
tors early in the life course, rather than in late adulthood,
might be a more effective strategy to prevent high blood
Table 3: Multilevel regression analysis of systolic blood pressure (SBP) in 1926 individuals from 438 Swedish families with hypertension
Model I (empty) Model II Model III
Fixed effects
Intercept (mmHg)
139.17 (0.64) 141.78 (1.50) 143.23 (1.66)
Regression coefficient (SE)
Age (years) - 0.90 (0.03) 0.90 (0.03)
Sex (men vs. women) - -0.23 (0.81)NS -0.20 (0.83)NS
ACE inhibitors use (yes vs. no) Cohort - 4.51 (1.66) 4.33 (1.62)
Skara - Reference Reference
Malmö A - -7.64 (1.68) -7.49 (1.67)
Malmö B - -0.96 (1.60)NS -0.87 (1.59)NS
ACE gene I/D polymorphism
II - - Reference
ID - - -2.38 (1.06)
DD - - -1.48 (1.21)NS
Random effects
Variance (SE)
Individual level 511.50 (19.00) 290.01 (11.17) 290.32 (11.02)
Familial intercept 50.40 (12.34) 30.22 (6.45) 28.58 (7.56)
Age-SBP slope - 0.04 (0.01) 0.04 (0.01)
ACE inhibitors-SBP slope - 142.46 (54.90) 131.04 (48.83)
Covariance (SE)
Age-intercept - 0.99 (0.21) 0.96 (0.23)
ACE inhibitors-intercept - -22.62 (16.51) -18.40 (14.62)
Age-ACE inhibitors - -0.70 (0.61) -0.66 (0.59)
VPC (%)
9 See figure 2 See figure 2
Goddness of the fit
DIC (MCM) 16978 15898 15897
VPC: Variance partition coefficient. DIC: Deviance Information Criterion. MCMC: Markov Chain Monte CarloBMC Medical Genetics 2006, 7:14 http://www.biomedcentral.com/1471-2350/7/14
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shows the differences in the slope (each line represents a family) of the association between on the one hand age (A) and use  of ACE inhibitors (B) and other hand SBP level Figure 1
shows the differences in the slope (each line represents a family) of the association between on the one hand age (A) and use 
of ACE inhibitors (B) and other hand SBP level. Simple visual observation suggests that there is considerable familial heteroge-
neity (i.e., family-individual interactions) in those associations. Observe that the regression lines are model predictions obtained 
in model II.
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pressure in the population. [26] Future research will iden-
tify which those factors and how we can influence them.
The degree of familial clustering of SBP level was much
higher in users of ACE-inhibitors than in non-users (Fig-
ure 2B) and this clustering was also considerably less age
dependent. This observation indicates that ACE inhibitors
produce a more intense blood pressure lowering effect in
some families than in others. One reason for this familial
heterogeneity might be genetic differences in the suscepti-
bility to the effect of ACE inhibitor, and our hypothesis
was that the ACE I/D polymorphism could be a candidate
for explaining these familial differences. We also observed
that – as expected – the different forms of the ACE I/D pol-
ymorphism presented a high degree of clustering within
families. However, accounting for differences in the ACE
I/D polymorphism explained only a minor part of the
familial differences in SBP level among user of ACE inhib-
itors.
The role of the ACE I/D polymorphism in blood pressure
regulation has been extensively studied. Although there is
no doubt that the polymorphism is associated with
plasma ACE activity, there is less evidence on the role of
ACE I/D polymorphism in blood pressure regulation.
[5,27] Blood pressure is a complex trait that results from
the effect of multiple genes and many environmental
influences [28]. There is a growing agreement from many
studies in that single gene effects on antihypertensive drug
responses are small, and even the combined effects of all
presently known polymorphisms do not account for
enough variation in response to be clinically useful.[29]
With this in mind, it is not surprising that the ACE I/D
polymorphism only explained a very small part of the
total familial variance in SBP level. Nevertheless our
results suggest that the ACE I/D polymorphism might
have some role in blood pressure control among users of
ACE inhibitors.
ACE-inhibition was not a first-line antihypertensive ther-
apy in Sweden at the time of patient-recruitment in the
present study, indicating that these patients had
responded less well on conventional treatment (thiazides
and beta-blockers) or that they had concomitant diseases
such as diabetes with microalbuminuria or heart failure.
One possible explanation for the greater familial cluster-
ing of SBP in users than in non-users of ACE inhibitors
could thus be that patients treated with ACE-inhibitors
illustrates the variance between families in SBP and the familial clustering of SBP level (i.e., VPC) along individual age and in  users and non-users of ACE-inhibitors Figure 2
illustrates the variance between families in SBP and the familial clustering of SBP level (i.e., VPC) along individual age and in 
users and non-users of ACE-inhibitors. Because of the existence of slope variance (Figure 1) the familial SBP variance (Figure 
2A) and the VPC (Figure 2B) became a function of age and use of ACE inhibitors. Familial clustering of SBP (i.e., VPC) seems 
increase with age and this effect is more evident among non users of ACE inhibitors. In users of ACE inhibitors familial cluster-
ing of SBP is already evident in younger ages. Inclusion of the ACE gene I/D polymorphism in model III (red colour) reduces the 
familial clustering of SBP even if this effect is small. Consider that the estimations are insecure at ends of the curves since the 
number of individuals is small. The information illustrated in figure 2 is also numerically presented in table 4.
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had more atherosclerosis and endothelial dysfunction
than non-users of ACE inhibitors. In analogy with the
effect of age on familial SBP clustering in non-users, it can
be speculated that genetic and familial environmental fac-
tors affecting SBP have a greater impact when acting on
the background of a relatively more pathological or "bio-
logically aged" vascular system.
Most patients treated with ACE inhibitors were also on
treatment with other antihypertensive agents, mostly
beta-receptor blockers (i.e., 32%) and calcium channel
blockers (i.e., 27%) introducing some uncertainty as to
how much of the on-treatment blood pressure level was
influenced by overall drug effects as opposed to ACE-
inhibitor specific effects. However, adjustment for use of
those medications in model III had only a minor effect on
the slope variance, which was reduced from 131 to 128
(not show in tables).
Conclusion
We advocate a study design that may be useful for study-
ing the influence of genetic and environmental familial
factors in public health. This approach may facilitate the
investigation of common processes that with multifaceted
expression and development across time in different con-
texts. Multilevel regression analysis [10] emerges as an
appropriate tool for investigating complex patterns of var-
iance, an aspect that is especially useful in genetic epide-
miology where the information has a natural hierarchical
structure (e.g., pedigrees, generations, individuals)
[12,13].
Our study suggest that familial circumstances (genetic,
environmental or their interaction) condition individual
SBP level and seems to modify the effect of ACE inhibi-
tors, a fact that deserves more investigation in order to
improve the effectiveness of pharmacological treatment of
hypertension. Familial circumstances also seem to play a
relevant role for understanding SBP level in non-users of
ACE inhibitors but those effects express later in the life
course. Those facts suggests that strategies directed to pre-
vent hypertension should be launched in younger rather
than in older ages and both prevention of hypertension
and its treatment with ACE inhibitors should be focused
on families rather than on individuals.
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